An investigation into the molecular causes of a debilitating condition known as "Man on Fire Syndrome" has led Yale researchers to develop a strategy that may lead to personalized pain therapy and predict which chronic pain patients will respond to treatment.
More than a quarter of Americans suffer from chronic pain and nearly 40 percent do not get effective relief from existing drugs. In many common conditions such as diabetic neuropathy, no clear source of pain is found.
The new study published in the Nov. 13 issue of Nature Communications used sophisticated atomic modeling techniques to search for mutations found in a rare, agonizing, and previously untreatable form of chronic pain called erythromelagia, commonly referred to as "Man on Fire Syndrome." Researchers discovered that one of those mutations seem to predicted whether a patient would respond positively to drug treatment.
"Hopefully we can use this knowledge to help chronic pain patients in more systematic ways, and not depend upon trial and error," said Yang Yang, postdoctoral research associate in the Department of Neurology and lead author of the paper.
Under the leadership of Stephen Waxman, the Bridget Marie Flaherty Professor of Neurology, professor of neurobiology and of pharmacology, and senior author of the new paper, Yale has been a leader in identifying the sodium channel Nav1.7 at the base nerve cells as the regulator of several forms of chronic pain. The members of the Waxman lab were intrigued when it was reported the anti-seizure medicine carbamazepine relieved pain in members of a family suffering from erythromelagia, apparently by working on the Nav 1.7 sodium channel.
Yale researchers conducted an exhaustive genetic analysis and discovered that a specific variant — a difference of a single amino acid among 1,800 — in the sodium channel explained why this family responded to the drug. In this new paper, the Yale team developed a three-dimensional structural model of human Nav1.7 channel and systemically looked at different erythromelagia mutations at the atomic level. The Yale team found an additional, second mutation that was sensitive to carbamazepine treatment. In theory, chronic pain patients with this mutation should respond to treatment with carbamazepine.
"This work shows us that the goal of personalized, genomically-guided drug treatment for pain is not unrealistic," Waxman said.
Yale University: http://www.yale.edu
This press release was posted to serve as a topic for discussion. Please comment below. We try our best to only post press releases that are associated with peer reviewed scientific literature. Critical discussions of the research are appreciated. If you need help finding a link to the original article, please contact us on twitter or via e-mail.
For the first time, researchers have tracked the spread of Ebola, almost in real time, during an outbreak. The virus is quickly changing its DNA. But it's still unclear what these mutations mean.
Think of all the adults you know. Think of your parents and grandparents. Think of the teachers you had at school, your doctors and dentists, the people who collect your rubbish, and the actors you see on TV. All of these people probably have little mites crawling, eating, sleeping, and having sex on their faces.
A trial vaccine against Ebola could be tested on healthy volunteers in the UK in September, says an international health consortium.
The ALS Association has raised more than $94 million in recent weeks via its online ice bucket challenge — compared with $2.7 million this time last year. Now what?
Implant attached to bone in pioneering technique that helps prevent infection and discomfort
A new method for removing allergens from peanuts means help could soon be on the way for the roughly 2.8 million Americans with a potentially life-threatening allergy to the popular food, the U.S. Department of Agriculture said on Tuesday.
Survey finds many social media users hesitate to express opinions unless they know their followers will agree with them
Ebola has a nasty reputation for damaging the body, especially its blood vessels. But when you look at the nitty-gritty details of what happens after a person is infected, a surprising fact surfaces.
You think bringing a new toothbrush to market is easy? The seven-year saga of two dental entrepreneurs struggling to bring their patented brush to consumers suggests otherwise.
Scholars have long tried to understand how culture affects communities. New research argues that the parking behavior of drivers may tell us something about the economic productivity of nations.